News

The randomized, crossover study Phase IIb trial is designed to evaluate the safety, tolerability and efficacy of three different doses of ALLN-177 for reducing urinary oxalate excretion in

This agreement will complement Flexion’s existing manufacturing relationship with Evonik Corporation and create redundant supply for FX006, which is an intra-articular (IA) sustained-release steroid for the treatment of

Minerva Biotechnologies discovered a naturally occurring, primitive growth factor that continues this reprogramming to an even earlier, embryonic-like point called the ‘naïve’ state. Scientists believe that because these

Insulin glargine 300 units/ml is indicated for the treatment of diabetes mellitus in adults and is a novel formulation of the glargine molecule Lantus (insulin glargine 100 units/mL)

The company noted that in a Phase I trial, low-dose veltuzumab, as a single agent, produced an objective response rate of 55% in 38 response-assessable patients with relapsed

The EC’s decision includes Pfizer’s commitment to divest certain sterile injectable drugs and its infliximab biosimilar drug, which is currently under development. Pfizer chairman and chief executive officer

ALX-0061 targets the interleukin 6 pathway via its IL-6 receptor (IL-6R) and is being developed to treat rheumatoid arthritis (RA) and SLE. The trial is designed to identify

A4 is a new clinical trial evaluating solanezumab in the preclinical stage of Alzheimer’s disease in older individuals who have evidence of amyloid in their brains on a

Par’s ethacrynate sodium is the generic version of Valeant Pharmaceuticals North America division Aton Pharma’s Sodium Edecrin, which is indicated for the treatment of edema. According to the